Navigation Links
Watson Confirms Court Decision Rejecting Teva's Motion to Prevent Launch of Generic SEASONIQUE®
Date:6/17/2011

PARSIPPANY, N.J., June 17, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, today confirmed that the United States District Court for the District of Nevada denied Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction and request for a temporary restraining order preventing Watson's launch of generic SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg). The company is evaluating plans to launch the contraceptive product.

On March 25, 2011, Watson received a favorable decision from the United States Court of Appeals for the Federal Circuit that reversed and remanded for trial a March 31, 2010 summary judgment order from the United States District Court for the District of Nevada regarding United States Patent No. 7,320,969 (the '969 patent).

On January 22, 2008, Watson notified Teva Women's Health that Watson's ANDA contained a paragraph IV certification asserting that the '969 patent is invalid, unenforceable and/or not infringed.

SEASONIQUE® is indicated for the prevention of pregnancy.

SEASONIQUE® is a registered trademark of Teva Women's Health, Inc.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to no
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watsons Nabumetone Tablets Receive FDA Approval
2. Watson Confirms Pataday™ Patent Challenge
3. Watson Confirms Viagra® Patent Challenge
4. Watson to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
5. Watson Launches Generic AMRIX®
6. Watson Launches Generic Concerta®
7. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
8. Watson First Quarter 2011 Net Revenue Increases to $877 Million
9. New Life Agency Adds Watson to Join Walgreens on The Fertility Pharmacy Care Card for Fertility Medication
10. Watson Confirms Welchol® Patent Challenge
11. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Decision ... colitis (CD/UC) patients eligible for biologic therapy, ... a biologic. Surveyed gastroenterologists cite patients, discomfort ... for low penetration rates, followed by cost-related ... UC patients receiving biologics, Janssen Biotech,s Remicade ...
(Date:9/17/2014)... Sept. 17, 2014  Rebiotix Inc. announced this morning that ... product candidate, RBX2660 (microbiota suspension) will be presented in two ... in Philadelphia from October 8-12. ... the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety ...
(Date:9/17/2014)... , Sept. 17, 2014   OTEMR, Inc. , ... Complete EHR certification, which designates that the software is ... 1 and Stage 2 Meaningful Use measures required to ... Act (ARRA).  ONETOUCH EMR 2.0 was certified on July ... of the National Coordinator-Authorized Certification Body (ONC-ACB) and is ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3
... recommendations for knee and ... hip osteoarthritis, ... MT. LAUREL, N.J., Feb. 19 A newly released set ... worldwide who live in pain due to inconsistent treatment,approaches and confusion ...
... Feb. 19 Joseph F. Finn, Jr.,CPA, the ... announced,today the design of a clinical trial to ... approved antibiotics. Rifalazil, the,most potent anti-chlamydial agent that ... treatment option for Chlamydia STD. The insidious aspect,of ...
Cached Medicine Technology:Osteoarthritis: Which Treatments Work and Which Don't? 2Osteoarthritis: Which Treatments Work and Which Don't? 3ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD 2
(Date:9/18/2014)... September 18, 2014 First Choice ... emergency rooms in the United States, named Douglas J. ... Missouri City-Lakes facility. , “We are pleased to ... medical director of our new Missouri City-Lakes facility,” said ... Choice Emergency Room. , Dr. Harrison received his ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 The Nautilus/ASG ... from active, to medium, and even long term data ... for any length of time. This includes media and ... data. When used together, Nautilus and ASG-Digital Archive will ... content. , "storageFOUNDRY is pleased to work with ...
(Date:9/17/2014)... 2014 The global ablation technologies market ... from 2014 to 2019. Although mature markets (such as ... shares in the ablation technologies market in 2014, the ... CAGR of 12.8% in the next five years.Factors such ... growing number of hospitals and surgical centers, and the ...
(Date:9/17/2014)... 18, 2014 Dr. Shalev is a Texas ... Houston to study at the University of Texas, and graduated ... she realized her real passion lay in dentistry, and she ... the University of Texas Health Science Center at Houston School ... is a member of The Greater Houston Dental Society, and ...
(Date:9/17/2014)... New York, NY (PRWEB) September 18, 2014 ... than 5.9 million tons of medical waste in 2014. ... directly disposed of in landfills along with municipal solid ... the disposal of regulated medical waste (RMW). This includes ... fluids or other potentially infectious materials. As a result ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 3
... Society report outlines 21 challenges and needs for global tobacco ... and expertise needed to reduce the rising tide of tobacco ... are the target of the multinational tobacco industry. The report ... issue of CA: A Cancer Journal for Clinicians . ...
... Genital herpes caused by a reactivation of herpes simplex ... lesion in one specific area of the genital region. ... frequently reactivate throughout the genital tract, an important new ... prevention. Now available online ( http://www.journals.uchicago.edu/doi/abs/10.1086/650302 ), the study ...
... is associated with increased cancer risk. The most ... noted for a common form of liver cancer called ... obesity in mice, researchers at the University of California, ... obesity is tumor-promoting and have obtained evidence that this ...
... Hasbro Children,s Research Center and Hasbro Children,s Hospital researchers ... from The Eunice Kennedy Shriver National Institute of Child ... of asthma on the sleep quality and academic performance ... pediatric researchers, led by Daphne Koinis-Mitchell, PhD, to evaluate ...
... reduce the transmission of influenza-like illness during flu season. ... online ( http://www.journals.uchicago.edu/doi/abs/10.1086/650396 ), published in the Feb. 15 ... In an influenza pandemic, vaccination may not be ... is why scientists need to understand how effective other ...
... The BC Centre for Disease Control has launched ... the pandemic H1N1 flu virus has evolved in British ... months. This project capitalizes on BC,s expertise and ... genomes from circulating influenza viruses collected in British Columbia ...
Cached Medicine News:Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Study shows genital herpes virus reactivates widely throughout genital tract 2Health News:Link between obesity and enhanced cancer risk elucidated 2Health News:New research will examine link between childhood asthma, sleep and school performance 2Health News:Study finds face masks and hand hygiene can help limit influenza's spread 2Health News:Genomic surveillance of pandemic H1N1 2
... Ultracentrifuge power for small-volume samples. With ... method of removing chylomicrons (fat particles in ... results for lipemic clarification. Lipemic samples can ... need for sendouts. The easy-to-operate tabletop ...
... Dimension Xpand integrated chemistry system brings ... to the smaller laboratory. A model ... Xpand integrated chemistry system features state-of-the-art ... low-volume testing environment, in a flexible, ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... Dimension clinical chemistry integrated systems combine the ... cartridge, the power of the Multiply and ... the heterogeneous module to meet the challenges ... broad test menus, the systems can meet ...
Medicine Products: